Predicting risk of coronary events and all-cause mortality: role of B-type natriuretic peptide above traditional risk factors and coronary artery calcium scoring in the general population: the Heinz Nixdorf Recall Study

Aims Several biomarkers including B-type natriuretic peptide (BNP) have been suggested to improve prediction of coronary events and all-cause mortality. Moreover, coronary artery calcium (CAC) as marker of subclinical atherosclerosis is a strong predictor for cardiovascular mortality and morbidity. We aimed to evaluate the predictive ability of BNP and CAC for all-cause mortality and coronary events above traditional cardiovascular risk factors (TRF) in the general population. Methods We followed 3782 participants of the population-based Heinz Nixdorf Recall cohort study without coronary artery disease at baseline for 7.3 ± 1.3 years. Associations of BNP and CAC with incident coronary events and all-cause mortality were assessed using Cox regression, Harrell’s c, and time-dependent integrated discrimination improvement (IDI(t), increase in explained variance). Results Subjects with high BNP levels had increased frequency of coronary events and death (coronary events/mortality: 14.1/28.2% for BNP ≥100 pg/ml vs. 2.7/5.5% for BNP < 100 pg/ml, respectively). Subjects with a BNP ≥100 pg/ml had increased incidence of hard endpoints sustaining adjustment for CAC and TRF (for coronary events: hazard ratio (HR) (95% confidence interval (CI)) 3.41(1.78–6.53); for all-cause mortality: HR 3.35(2.15–5.23)). Adding BNP to TRF and CAC increased measures of predictive ability: coronary events (Harrell’s c, for coronary events, 0.775–0.784, p = 0.09; for all-cause mortality 0.733–0.740, p = 0.04; and IDI(t) (95% CI), for coronary events: 2.79% (0.33–5.65%) and for all-cause mortality 1.78% (0.73–3.10%). Conclusions Elevated levels of BNP are associated with excess incident coronary events and all-cause mortality rates, with BNP and CAC significantly and complementary improving prediction of risk in the general population above TRF.

[1]  C. Lang,et al.  Improving the primary prevention of cardiovascular events by using biomarkers to identify individuals with silent heart disease. , 2012, Journal of the American College of Cardiology.

[2]  M. Cameli,et al.  B-type natriuretic peptide as an independent predictor of coronary disease extension in non-ST elevation coronary syndromes with preserved systolic function , 2012, European journal of preventive cardiology.

[3]  M. Volpe,et al.  Circulating biomarkers with preventive, diagnostic and prognostic implications in cardiovascular diseases. , 2012, International journal of cardiology.

[4]  Sex-specific threshold levels of plasma B-type natriuretic peptide for prediction of cardiovascular event risk in a Japanese population initially free of cardiovascular disease. , 2011, The American journal of cardiology.

[5]  S. Moebus,et al.  Quantification of coronary atherosclerosis and inflammation to predict coronary events and all-cause mortality. , 2011, Journal of the American College of Cardiology.

[6]  Lloyd E Chambless,et al.  Several methods to assess improvement in risk prediction models: Extension to survival analysis , 2011, Statistics in medicine.

[7]  Klaus Mann,et al.  Coronary risk stratification, discrimination, and reclassification improvement based on quantification of subclinical coronary atherosclerosis: the Heinz Nixdorf Recall study. , 2010, Journal of the American College of Cardiology.

[8]  A. Hofman,et al.  Amino-Terminal Pro–B-Type Natriuretic Peptide Improves Cardiovascular and Cerebrovascular Risk Prediction in the Population: The Rotterdam Study , 2010, Hypertension.

[9]  D. de Zeeuw,et al.  N-terminal pro-B-type natriuretic peptide is an independent predictor of cardiovascular morbidity and mortality in the general population. , 2010, European heart journal.

[10]  J. Danesh,et al.  B-Type Natriuretic Peptides and Cardiovascular Risk: Systematic Review and Meta-Analysis of 40 Prospective Studies , 2009, Circulation.

[11]  D. Berman,et al.  Prognostic accuracy of B-natriuretic peptide measurements and coronary artery calcium in asymptomatic subjects (from the Early Identification of Subclinical Atherosclerosis by Noninvasive Imaging Research [EISNER] study). , 2009, The American journal of cardiology.

[12]  M. Pencina,et al.  Novel and conventional biomarkers for prediction of incident cardiovascular events in the community. , 2009, JAMA.

[13]  D. Grönemeyer,et al.  Smoking cessation and subclinical atherosclerosis--results from the Heinz Nixdorf Recall Study. , 2009, Atherosclerosis.

[14]  R. Kronmal,et al.  Coronary calcium predicts events better with absolute calcium scores than age-sex-race/ethnicity percentiles: MESA (Multi-Ethnic Study of Atherosclerosis). , 2009, Journal of the American College of Cardiology.

[15]  J. Sundström,et al.  Use of multiple biomarkers to improve the prediction of death from cardiovascular causes , 2008 .

[16]  D. Grönemeyer,et al.  Sex related cardiovascular risk stratification based on quantification of atherosclerosis and inflammation. , 2008, Atherosclerosis.

[17]  Moyses Szklo,et al.  Coronary calcium as a predictor of coronary events in four racial or ethnic groups. , 2008, The New England journal of medicine.

[18]  M. Pencina,et al.  Evaluating the added predictive ability of a new marker: From area under the ROC curve to reclassification and beyond , 2008, Statistics in medicine.

[19]  S. Moebus,et al.  Comparison of subclinical coronary atherosclerosis and risk factors in unselected populations in Germany and US-America. , 2007, Atherosclerosis.

[20]  Mark A. Hlatky,et al.  ACCF/AHA 2007 Clinical Expert Consensus Document on Coronary Artery Calcium Scoring By Computed Tomography in Global Cardiovascular Risk Assessment and in Evaluation of Patients With Chest Pain , 2007 .

[21]  Daniel S Berman,et al.  Coronary artery calcium as a measure of biologic age. , 2006, Atherosclerosis.

[22]  D. Grönemeyer,et al.  Population-based assessment of subclinical coronary atherosclerosis using electron-beam computed tomography. , 2006, Atherosclerosis.

[23]  R. Redberg Coronary artery calcium: should we rely on this surrogate marker? , 2006, Circulation.

[24]  A. Khera,et al.  Relation of coronary atherosclerosis determined by electron beam computed tomography and plasma levels of n-terminal pro-brain natriuretic peptide in a multiethnic population-based sample (the Dallas Heart Study). , 2005, The American journal of cardiology.

[25]  C. Camargo,et al.  The N-terminal Pro-BNP investigation of dyspnea in the emergency department (PRIDE) study. , 2005, The American journal of cardiology.

[26]  D. Levy,et al.  Plasma natriuretic peptide levels and the risk of cardiovascular events and death , 2004 .

[27]  J. Rehfeld,et al.  Increased cardiac BNP expression associated with myocardial ischemia , 2003, FASEB journal : official publication of the Federation of American Societies for Experimental Biology.

[28]  P. Ferdinandy,et al.  B-type natriuretic peptide limits infarct size in rat isolated hearts via KATP channel opening. , 2003, American journal of physiology. Heart and circulatory physiology.

[29]  D. Grönemeyer,et al.  Assessment of clinically silent atherosclerotic disease and established and novel risk factors for predicting myocardial infarction and cardiac death in healthy middle-aged subjects: rationale and design of the Heinz Nixdorf RECALL Study. Risk Factors, Evaluation of Coronary Calcium and Lifestyle. , 2002, American heart journal.

[30]  Alan S Maisel,et al.  Rapid measurement of B-type natriuretic peptide in the emergency diagnosis of heart failure. , 2002, The New England journal of medicine.

[31]  M. Ohyanagi,et al.  Transient increase in plasma brain (b‐type) natriuretic peptide after percutaneous transluminal coronary angioplasty , 2000, Clinical cardiology.

[32]  K. Bailey,et al.  Superiority of brain natriuretic peptide as a hormonal marker of ventricular systolic and diastolic dysfunction and ventricular hypertrophy. , 1996, Hypertension.

[33]  H. Itoh,et al.  Rapid ventricular induction of brain natriuretic peptide gene expression in experimental acute myocardial infarction. , 1995, Circulation.

[34]  K. Kugiyama,et al.  Localization and Mechanism of Secretion of B‐Type Natriuretic Peptide in Comparison With Those of A‐Type Natriuretic Peptide in Normal Subjects and Patients With Heart Failure , 1994, Circulation.

[35]  Z. Ying,et al.  Checking the Cox model with cumulative sums of martingale-based residuals , 1993 .

[36]  S. Yusuf,et al.  Comparison of neuroendocrine activation in patients with left ventricular dysfunction with and without congestive heart failure. A substudy of the Studies of Left Ventricular Dysfunction (SOLVD). , 1990, Circulation.

[37]  R. Detrano,et al.  Quantification of coronary artery calcium using ultrafast computed tomography. , 1990, Journal of the American College of Cardiology.

[38]  David A. Schoenfeld,et al.  Partial residuals for the proportional hazards regression model , 1982 .